A new prostate cancer therapy in clinical trials could treat patients resistant to treatment through targeting the disease on a molecular level, based on Cleveland Clinic research.
New Genetic Test May Mean Better Outcomes in Advanced Prostate Cancer
A new test developed at Cleveland Clinic interrogates the HSD3B1 gene to determine if a prostate cancer patient has inherited the adrenal-permissive (1245C) or adrenal-restrictive (1245A) allele. The development of the test is an outgrowth of more than seven years of research at Cleveland Clinic.
A New Paradigm for Advanced Prostate Cancer Clinical Trials
If therapies for advanced prostate cancer — particularly those with curative intent for oligometastatic disease — are to progress, clinical trials will need to take into account what’s driving tumor progression, what treatment will add benefit, and for which patients, contends eminent cancer researcher Nima Sharifi, MD.
Prostate Cancer Drug Metabolite May Fuel Cancer Cells
Men with the HSD3B1(1245C) variant metabolize abiraterone differently and have high levels of a metabolite called 3-keto-5α-abiraterone.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
New Research Links Gene Variant to Deadly Prostate Cancer
A research team led by noted Cleveland Clinic physician-researcher Nima Sharifi, MD, is honing in on what makes certain men more susceptible to prostate cancer that is likely to progress from hormone-sensitive to castration-resistant.
Researchers Find Mutation That Promotes Hormone Therapy Resistance
Cleveland Clinic researchers have discovered the first example of a genetic alteration that increases the conversion of precursor steroids to 5α-dihydrotestosterone (DHT), permitting prostate tumors to grow in the absence of gonadal testosterone.
Researchers Find Mutation That Promotes Hormone Therapy Resistance
Cleveland Clinic researchers have discovered the first example of a genetic alteration that increases the conversion of precursor steroids to 5α-dihydrotestosterone (DHT), permitting prostate tumors to grow in the absence of gonadal testosterone.